LISATA THERAPEUTICS, INC.
LSTA evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Market Cap:
- $14.7M
- Lead Asset:
- certepetide (Phase 2)
What it means
What to watch
Prepared research question
What matters most for LSTA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LSTA
Lisata Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and cardioendocrine diseases, currently undergoing a strategic acquisition by Kuva Labs and concurrently acquiring Marea Therapeutics.
Key risk: Clinical trial failure
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials · 1 catalyst for LISATA THERAPEUTICS, INC..
Lisata Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and cardioendocrine diseases, currently undergoing a strategic acquisition by Kuva Labs and concurrently acquiring Marea Therapeutics.
- Lisata is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies [sec_mda · as of 2026-03-12].
- As of 2026-06-30, the company reported cash & equivalents of $10.4M, zero revenue, a net loss of $2.9M, and shareholders' equity of $8.2M [sec].
- The company announced the acquisition of Marea Therapeutics and a concurrent $225 million private placement, with combined operations focused on cardioendocrine diseases and projected funding into 2028 [news · published 2026-09-17].
- Lisata's lead oncology candidate, certepetide, is being evaluated in a Phase 1b/2a trial (FORTIFIDE) for metastatic pancreatic ductal adenocarcinoma, with a planned start date of 2030-01-01 [catalyst].
- The proposed acquisition of Lisata by Kuva Labs, Inc. is noted as a key factor that could affect the company's future [sec · filed 2026-04-28].
What works
- The company has secured a $225 million private placement from leading life sciences investors, projected to fund operations into 2028 [news · published 2026-09-17].
- Lisata's acquisition of Marea Therapeutics brings multiple late-stage clinical candidates, including MAR001/005 for severe hypertriglyceridemia (Phase 2b) and MAR002 for acromegaly (advancing to Phase 2) [news · published 2026-09-17].
- The company maintains a diversified pipeline with both oncology (certepetide) and cardioendocrine programs, spreading development risk [sec_mda · as of 2026-03-12].
What to weigh
- Lisata reported zero revenue and a net loss of $2.9M as of 2026-06-30, with cash & equivalents of only $10.4M, indicating a limited cash runway without the new financing [sec].
- The company faces inherent uncertainties in clinical development, including the risk that preclinical or clinical results may not support further development of product candidates [sec · filed 2026-06-01].
- The proposed acquisition by Kuva Labs introduces transaction-related risks, including potential delays or failure to close [sec · filed 2026-04-28].
- Lisata's dependence on successful clinical development, regulatory approval, and commercialization of its product candidates is a key structural challenge [sec · filed 2026-05-29].
From the filings
Quoted directly from source documents.
Lisata is a clinical-stage pharmaceutical company
“We are a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative the”
SEC MD&A · March 12, 2026
Acquisition of Marea Therapeutics and $225 million private placement
“Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement”
News · September 17, 2026
Proposed acquisition by Kuva Labs
“the proposed acquisition of our company by Kuva Labs, Inc., including the anticipated time frame for completion of the transaction”
SEC filings · April 28, 2026
Catalyst timeline
- 2030-01-01 · Phase2_Start: A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE) — This trial initiation will test certepetide in combination with standard of care for metastatic pancreatic cancer, a key pipeline milestone.
Risks & what to watch (4)›
Key risks
- Clinical trial failure — Preclinical or clinical results may not support further development of product candidates [sec · filed 2026-06-01].
- Cash runway limited — Cash & equivalents of $10.4M as of 2026-06-30, with zero revenue and ongoing net losses [sec].
- Acquisition uncertainty — Proposed acquisition by Kuva Labs may not close as anticipated [sec · filed 2026-04-28].
- Regulatory approval dependency — Company depends on successful clinical development, regulatory approval, and commercialization [sec · filed 2026-05-29].
What to watch
- Completion of the acquisition by Kuva Labs and the concurrent acquisition of Marea Therapeutics [sec · filed 2026-04-28] [news · published 2026-09-17].
- Progress of the Phase 1b/2a FORTIFIDE trial for certepetide in metastatic pancreatic cancer, with a planned start date of 2030-01-01 [catalyst].
- Advancement of Marea's late-stage candidates: MAR001/005 Phase 2b for severe hypertriglyceridemia and MAR002 Phase 2 for acromegaly [news · published 2026-09-17].
- Cash runway and burn rate following the $225 million private placement, projected to fund operations into 2028 [news · published 2026-09-17].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run LISATA THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LISATA THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.37 · 0% dilution
Lead: Phase 2
2 candidates
1 upcoming, next in ~1176d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
35
Total value held
$5.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 271,815 | $1.4M |
| renaissance technologies llc | 131,715 | $660K |
| deltec asset management llc | 90,000 | $451K |
| rangeley capital, llc | 75,000 | $376K |
| geode capital management, llc | 70,887 | $355K |
| css llc/il | 61,898 | $310K |
| blackrock, inc. | 54,857 | $275K |
| penderfund capital management ltd. | 47,500 | $238K |
| vanguard fiduciary trust co | 34,917 | $175K |
| gts securities llc | 31,396 | $157K |
Showing top 10 of 35 institutional holders of LISATA THERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 0.7%
- Days to cover
- 0.7
- Shares short
- 51,644
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LSTA short interestGovernance
Frequently asked questions
What is the AI investment thesis for LISATA THERAPEUTICS, INC.?
Lisata Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and cardioendocrine diseases, currently undergoing a strategic acquisition by Kuva Labs and concurrently acquiring Marea Therapeutics.
What is LISATA THERAPEUTICS, INC.'s lead drug candidate?
LISATA THERAPEUTICS, INC.'s most advanced tracked candidate is certepetide (Phase 2) for Cholangiocarcinoma; Pancreas Cancer.
What is LISATA THERAPEUTICS, INC.'s next catalyst?
LISATA THERAPEUTICS, INC.'s next tracked catalyst is a Phase2_Start event — "Phase2_Start: A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Intravenous Push Followed by a Continuous Infusion of Certepetide Over 4 Hours When Added to Standard of Care (SoC) Versus Two Intravenous Pushes of Certepetide When Added to SoC, Versus SoC Alone in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (FORTIFIDE)" — expected January 1, 2030.
Who is the CEO of LISATA THERAPEUTICS, INC.?
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. is the chief executive officer of LISATA THERAPEUTICS, INC. (LSTA).
Where is LISATA THERAPEUTICS, INC. headquartered?
LISATA THERAPEUTICS, INC. (LSTA) is headquartered in Basking Ridge, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.